STAT-3 activates NF-kB in chronic lymphocytic leukemia cells

Molecular Cancer Research

Volumn 9, Issue 4, 2011, Pages 507-515

  Liu, Zhiming ^a   Hazan Halevy, Inbal ^a   Harris, David M ^a   Li, Ping ^a   Ferrajoli, Alessandra ^a   Faderl, Stefan ^a   Keating, Michael J ^a   Estrov, Zeev ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN P50; STAT3 PROTEIN; SYNAPTOTAGMIN I;

ADULT; AGED; ARTICLE; CANCER CELL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMPLEX FORMATION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DNA BINDING;

AGED; AGED, 80 AND OVER; CELL NUCLEUS; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NF-KAPPA B P50 SUBUNIT; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA; TRANSCRIPTIONAL ACTIVATION;

EID: 79954551968     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0559     Document Type: Article

References (40)

1. Yee KW, O' , Brien SM. Chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 2006;81:1105-29. (Pubitemid 44175023)
2. Schuh K, Avots A, Tony HP, Serfling E, Kneitz C. Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients. Leuk Lymphoma 1996;23:583-92.
3. Sembries S, Pahl H, Stilgenbauer S, Dohner H, Schriever F. Reduced expression of adhesion molecules and cell signaling receptors by chronic lymphocytic leukemia cells with 11q deletion. Blood 1999;93:624-31. (Pubitemid 29035745)
4. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000;164:2200-6. (Pubitemid 30108780)
5. Bernal A, Pastore RD, Asgary Z, Keller SA, Cesarman E, Liou HC, et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 2001;98:3050-7.
6. Cuní S, Pérez-Aciego P, Pérez-Chacón G, Vargas JA, Sánchez A, Martín-Saavedra FM, et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004;18:1391-400. (Pubitemid 39136749)
7. Rodriguez A, Martinez N, Camacho FI, Ruíz-Ballesteros E, Algara P, García JF, et al. Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement. Clin Cancer Res 2004;10:6796-806. (Pubitemid 39383028)
8. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008;111:4681-9.
9. Pickering BM, de Mel S, Lee M, Howell M, Habens F, Dallman CL, et al. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 2007;26: 1166-77.
10. Lopez-Guerra M, Colomer D. NF-kappaB as a therapeutic target in chronic lymphocytic leukemia. Expert Opin Ther Targets 2010;14: 275-88.
11. Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH 3rd, et al. 17-DMAG targets the NF-{kappa}B family of proteins to induce apoptosis in CLL: clinical implications of HSP90 inhibition. Blood 2010;116:45-53.
12. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008;132:344-62.
13. Edelmann J, Klein-Hitpass L, Carpinteiro A, Führer A, Sellmann L, Stilgenbauer S, et al. Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells. Leuk Res 2008;32:1565-72.
14. Munzert G, Kirchner D, Stobbe H, Bergmann L, Schmid RM, Döhner H, et al. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood 2002;100: 3749-56. (Pubitemid 35303947)
15. Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of BCLL through an autocrine pathway. Blood 2004;103:679-88. (Pubitemid 38145555)
16. Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 2007;109:703-10. (Pubitemid 46105972)
17. Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, Reed JC, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005;106:1012-20. (Pubitemid 41076448)
18. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3:221-7.
19. Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F, et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998;92: 990-5. (Pubitemid 28355483)
20. Muzio M, Scielzo C, Bertilaccio MT, Frenquelli M, Ghia P, Caligaris- Cappio F. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol 2009;144:507-16.
21. Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K, et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009;113: 856-65.
22. Hammadi A, Billard C, Faussat AM, Kolb JP. Stimulation of iNOS expression and apoptosis resistance in B-cell chronic lymphocytic leukemia (B-CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-kappaB activation. Nitric Oxide 2008;19:138-45.
23. Blonska M, Lin X. CARMA1-mediated NF-kappaB and JNK activation in lymphocytes. Immunol Rev 2009;228:199-211.
24. Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U, et al. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci U S A 2008;105:19643-8.
25. Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007; 110:735-42. (Pubitemid 47105412)
26. Chen SS, Raval A, Johnson AJ, Hertlein E, Liu TH, Jin VX, et al. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2009;106:13433-8.
27. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR. Unphosphorylated STAT-3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 2007;21: 1396-408. (Pubitemid 46871042)
28. Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, Chen X, et al. STAT-3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood. 2010;115:2852-63.
29. Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, Levy DE, et al. Novel roles of unphosphorylated STAT-3 in oncogenesis and transcriptional regulation. Cancer Res 2005;65: 939-47. (Pubitemid 40216455)
30. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002;109Suppl: S81-96.
31. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853-66.
32. Bourillot PY, Aksoy I, Schreiber V, Wianny F, Schulz H, Hummel O, et al. Novel STAT-3 target genes exert distinct roles in the inhibition of mesoderm and endoderm differentiation in cooperation with Nanog. Stem Cells 2009;27:1760-71.
33. Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NFkappaB signaling module. Oncogene 2006;25:6706-16. (Pubitemid 44657847)
34. Reich NC, Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol 2006;6:602-12. (Pubitemid 44134093)
35. Liu L, McBride KM, Reich NC. STAT-3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc Natl Acad Sci U S A 2005;102:8150-5. (Pubitemid 40800058)
36. Yang J, Stark GR. Roles of unphosphorylated STATs in signaling. Cell Res 2008;18:443-51. (Pubitemid 351498851)
37. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006;25:6680-4. (Pubitemid 44657845)
38. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 1995;267:1485-8.
39. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, et al. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 1995;9: 1586-97.
40. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, et al. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 2003;102:987-95. (Pubitemid 36917794)